Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Curcumin suppresses fat tissue growth in rodent models

Curcumin, the major polyphenol found in turmeric, appears to reduce weight gain in mice and suppress the growth of fat tissue in mice and cell models.

18 May 2009

Pazopanib shows promise for aggressive thyroid cancer

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

17 May 2009

Protein kinase JNK1 identified as treatment target for retinopathy in premature babies

Results of a study in mice by researchers at the University of California, San Diego strongly suggest that the protein kinase JNK1 plays a key role in the development of retinopathy in premature infants.

4 May 2009

Pancreatic cancer cells targeted with combo therapy

A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report.

21 Apr 2009

Potential new drug blocks pathway of deadliest cancer

Scientists at Cancer Research Technology Ltd (CRT) will present exciting new findings showing that a potent and selective inhibitor of protein kinase D called CRT0066101, inhibits the growth of pancreatic tumours.

20 Apr 2009

Human foetal stem cells can effectively be used to treat back leg ischaemic ulcers

Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year.

20 Apr 2009

Scientists show how gene alteration can lead to the development of a type of brain cancer

An international team of scientists from the Moores Cancer Center at the University of California, San Diego, the University of North Carolina and several institutions in China have explained how a gene alteration can lead to the development of a type of brain cancer, and they have identified a compound that could staunch the cancer's growth.

14 Apr 2009

Avastin safe and effective at delaying tumor progression

The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

6 Apr 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

Protein ferritin in blood may hold key to stopping tumor growth in cancer patients

A recent discovery by researchers at Wake Forest University School of Medicine could clear the way for a new drug that inhibits tumor growth in cancer patients and could potentially help in the healing of wounds.

1 Apr 2009

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.

30 Mar 2009

RegeneRx reports phase II venous stasis trial results

Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.

29 Mar 2009

Nanoparticles open door to cancer prevention

Perhaps the best way to fight cancer is to prevent it from developing in the first place, and based on newly published research from investigators at the University of Wisconsin-Madison, nanoparticles may be able to make cancer chemoprevention a reality.

26 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

Paradox of cancer drugs gives clue to why some treatments fail

Cancer Research UK funded scientists have found that some types of cancer drugs called angiogenesis inhibitors can encourage tumour growth rather than stunt it - according to research published in Nature Medicine.

22 Mar 2009

New therapeutic approaches to castrate resistant prostate cancer

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24 th Annual Congress of the European Association of Urology in Stockholm, Sweden.

22 Mar 2009

Phylonix granted broad U.S. patent for assessing cardiac functions in Zebrafish

Phylonix Pharmaceuticals announced, at the Society of Toxicology Annual Meeting in Baltimore, that the U.S. Patent and Trademark Office has issued the company a broad patent for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish.

15 Mar 2009

Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes

A study to determine if patients with type 2 diabetes can benefit from a combination of autologous (patient self-donated) stem cell infusions (ASC) and hyperbaric (above the normal air pressure of ) oxygen treatment (HBO) before and after ASC has found "significant benefits" in terms of "improvements in glycemic control" along with "reduced insulin requirements."

12 Mar 2009

Multiple route bone marrow stem cell injections show promise to treat spinal cord injury

Researchers from DaVinci Biosciences, Costa Mesa, California, in collaboration with Hospital Luis Vernaza in Ecuador, have determined that injecting a patient's own bone marrow-derived stem cells (autologous BMCs) directly into the spinal column using multiple routes can be an effective treatment for spinal cord injury (SCI) that returns some quality of life for SCI patients without serious adverse events.

12 Mar 2009